Lilly's ED treatment Cialis wins prostate indication

Eli Lilly ($LLY) just won FDA approval for an enlarged-prostate treatment. That's a bit of good news that only goes so far, as the market for benign prostatic hyperplasia treatments is rather full. The FDA counts 8 other drugs indicated to treat BPH, including Merck's ($MRK) Proscar, Pfizer's ($PFE) Cardura, Boehringer Ingelheim's Flomax, and GlaxoSmithKline's ($GSK) Avodart and Jalyn.

But the drug Lilly can now market as a BPH med is Cialis, the erectile dysfunction treatment. Men with enlarged prostates can get relief from those symptoms while enjoying a boost to their sex lives. Men who are self-conscious or embarrassed about seeking treatment for ED might be less hesitant to ask for a BPH therapy.

"BPH can have a big impact on a patient's quality of life," Scott Monroe, FDA's director of reproductive and urologic drugs, said in a statement. "A large number of older men have symptoms of BPH. Cialis offers these men another treatment option, particularly those who also have ED, which is also common in older men."

The new approval actually covers two indications: One for men with both ED and BPH symptoms, and one for men with BPH signs and symptoms only. FDA granted the new uses based on three studies, one in men with both conditions, and two in men with BPH.

- see the FDA statement
- get more from RTT News
- read the Reuters news

Suggested Articles

Six pharmaceutical execs are set to head to Washington next week for pricing hearings at the House Committee on Oversight and Reform. 

After sifting through the data, one analyst figures the latest Opdivo-Keytruda showdown in kidney cancer might come down to commercial execution.

Biogen is giving former chief finance officer Jeff Capello a multimillion-dollar cash payment plus other severance benefits.